Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Income Taxes

Microsoft Excel

Income Tax Expense (Benefit)

Bristol-Myers Squibb Co., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
U.S. 2,745 3,017 1,879 1,245 1,002
Non-U.S. 943 1,089 598 (104) 1,437
Current 3,688 4,106 2,477 1,141 2,439
U.S. (2,339) (2,889) (1,255) 229 (113)
Non-U.S. (949) 151 (138) 754 (811)
Deferred (3,288) (2,738) (1,393) 983 (924)
Provision for income taxes 400 1,368 1,084 2,124 1,515

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Current Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations. Bristol-Myers Squibb Co. current increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.
Deferred Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Bristol-Myers Squibb Co. deferred decreased from 2021 to 2022 and from 2022 to 2023.
Provision for income taxes Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Bristol-Myers Squibb Co. provision for income taxes increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.

Effective Income Tax Rate (EITR)

Bristol-Myers Squibb Co., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
U.S. statutory Federal income tax rate 21.00% 21.00% 21.00% 21.00% 21.00%
GILTI, net of foreign derived intangible income deduction 2.60% 8.20% 8.00% -10.00% 17.10%
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland -10.10% -5.40% -1.80% 1.30% -1.40%
Non-U.S. tax ruling -7.80% 0.00% 0.00% 0.00% 0.00%
Internal transfers of intangible and other assets 0.00% -1.20% -12.10% -12.40% 0.00%
U.S. Federal valuation allowance -2.00% 0.80% 0.10% 0.00% 0.00%
U.S. Federal, state and foreign contingent tax matters 1.70% -3.90% 1.90% -2.00% -0.30%
U.S. Federal research-based credits -2.90% -1.80% -2.00% 2.40% -2.80%
Charitable contributions of inventory -0.90% -1.20% -0.50% 0.50% 0.00%
Contingent value rights 0.00% 0.00% -1.30% 5.30% 2.20%
Non-deductible R&D charges 0.00% 0.00% 0.00% -35.80% 0.10%
Puerto Rico excise tax credit 0.00% -1.90% -1.90% 2.10% -3.30%
State and local taxes, net of valuation allowance 1.10% 1.30% 0.40% -1.50% -0.30%
Foreign and other 2.00% 1.80% 1.60% -1.80% -1.80%
Effective tax rate 4.70% 17.70% 13.40% -30.90% 30.50%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Effective tax rate Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Bristol-Myers Squibb Co. effective tax rate increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.

Components of Deferred Tax Assets and Liabilities

Bristol-Myers Squibb Co., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Foreign net operating loss and other carryforwards 2,017 566 945 3,271 2,480
State net operating loss and credit carryforwards 349 329 304 325 263
U.S. Federal capital loss, net operating loss and tax credit 249 236 226 435 88
Milestone payments and license fees 918 1,030 887 643 558
Capitalized research expenditures 2,682 1,573
Other 1,883 1,284 1,390 1,677 1,541
Deferred tax assets 8,098 5,018 3,752 6,351 4,930
Valuation allowance (764) (873) (1,056) (2,809) (2,844)
Deferred tax assets net of valuation allowance 7,334 4,145 2,696 3,542 2,086
Acquired intangible assets (4,052) (4,362) (4,867) (6,612) (7,387)
Goodwill and other (852) (605) (891) (1,176) (643)
Deferred tax liabilities (4,904) (4,967) (5,758) (7,788) (8,030)
Deferred tax assets (liabilities), net 2,430 (822) (3,062) (4,246) (5,944)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Deferred tax assets Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Bristol-Myers Squibb Co. deferred tax assets increased from 2021 to 2022 and from 2022 to 2023.
Deferred tax assets net of valuation allowance Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Bristol-Myers Squibb Co. deferred tax assets net of valuation allowance increased from 2021 to 2022 and from 2022 to 2023.
Deferred tax assets (liabilities), net Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. Bristol-Myers Squibb Co. deferred tax assets (liabilities), net increased from 2021 to 2022 and from 2022 to 2023.

Deferred Tax Assets and Liabilities, Classification

Bristol-Myers Squibb Co., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Deferred income taxes assets, non-current 2,768 1,344 1,439 1,161 510
Deferred income taxes liabilities, non-current 338 2,166 4,501 5,407 6,454

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Deferred income taxes assets, non-current Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent. Bristol-Myers Squibb Co. deferred income taxes assets, non-current decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Deferred income taxes liabilities, non-current Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent. Bristol-Myers Squibb Co. deferred income taxes liabilities, non-current decreased from 2021 to 2022 and from 2022 to 2023.

Adjustments to Financial Statements: Removal of Deferred Taxes

Bristol-Myers Squibb Co., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Adjustment to Total Assets
Total assets (as reported) 95,159 96,820 109,314 118,481 129,944
Less: Noncurrent deferred tax assets, net 2,768 1,344 1,439 1,161 510
Total assets (adjusted) 92,391 95,476 107,875 117,320 129,434
Adjustment to Total Liabilities
Total liabilities (as reported) 65,674 65,702 73,308 80,599 78,246
Less: Noncurrent deferred tax liabilities, net 338 2,166 4,501 5,407 6,454
Total liabilities (adjusted) 65,336 63,536 68,807 75,192 71,792
Adjustment to Total BMS Shareholders’ Equity
Total BMS shareholders’ equity (as reported) 29,430 31,061 35,946 37,822 51,598
Less: Net deferred tax assets (liabilities) 2,430 (822) (3,062) (4,246) (5,944)
Total BMS shareholders’ equity (adjusted) 27,000 31,883 39,008 42,068 57,542
Adjustment to Net Earnings (loss) Attributable To BMS
Net earnings (loss) attributable to BMS (as reported) 8,025 6,327 6,994 (9,015) 3,439
Add: Deferred income tax expense (benefit) (3,288) (2,738) (1,393) 983 (924)
Net earnings (loss) attributable to BMS (adjusted) 4,737 3,589 5,601 (8,032) 2,515

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Bristol-Myers Squibb Co., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Bristol-Myers Squibb Co., adjusted financial ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net Profit Margin
Reported net profit margin 17.83% 13.71% 15.08% -21.20% 13.15%
Adjusted net profit margin 10.53% 7.78% 12.08% -18.89% 9.62%
Total Asset Turnover
Reported total asset turnover 0.47 0.48 0.42 0.36 0.20
Adjusted total asset turnover 0.49 0.48 0.43 0.36 0.20
Financial Leverage
Reported financial leverage 3.23 3.12 3.04 3.13 2.52
Adjusted financial leverage 3.42 2.99 2.77 2.79 2.25
Return on Equity (ROE)
Reported ROE 27.27% 20.37% 19.46% -23.84% 6.66%
Adjusted ROE 17.54% 11.26% 14.36% -19.09% 4.37%
Return on Assets (ROA)
Reported ROA 8.43% 6.53% 6.40% -7.61% 2.65%
Adjusted ROA 5.13% 3.76% 5.19% -6.85% 1.94%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Financial ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Bristol-Myers Squibb Co. adjusted net profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted total asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023.
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.
Bristol-Myers Squibb Co. adjusted financial leverage ratio increased from 2021 to 2022 and from 2022 to 2023.
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity. Bristol-Myers Squibb Co. adjusted ROE deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level.
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted ROA deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.

Bristol-Myers Squibb Co., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS 8,025 6,327 6,994 (9,015) 3,439
Revenues 45,006 46,159 46,385 42,518 26,145
Profitability Ratio
Net profit margin1 17.83% 13.71% 15.08% -21.20% 13.15%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net earnings (loss) attributable to BMS 4,737 3,589 5,601 (8,032) 2,515
Revenues 45,006 46,159 46,385 42,518 26,145
Profitability Ratio
Adjusted net profit margin2 10.53% 7.78% 12.08% -18.89% 9.62%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Net profit margin = 100 × Net earnings (loss) attributable to BMS ÷ Revenues
= 100 × 8,025 ÷ 45,006 = 17.83%

2 Adjusted net profit margin = 100 × Adjusted net earnings (loss) attributable to BMS ÷ Revenues
= 100 × 4,737 ÷ 45,006 = 10.53%

Profitability ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Bristol-Myers Squibb Co. adjusted net profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Revenues 45,006 46,159 46,385 42,518 26,145
Total assets 95,159 96,820 109,314 118,481 129,944
Activity Ratio
Total asset turnover1 0.47 0.48 0.42 0.36 0.20
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Revenues 45,006 46,159 46,385 42,518 26,145
Adjusted total assets 92,391 95,476 107,875 117,320 129,434
Activity Ratio
Adjusted total asset turnover2 0.49 0.48 0.43 0.36 0.20

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Total asset turnover = Revenues ÷ Total assets
= 45,006 ÷ 95,159 = 0.47

2 Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= 45,006 ÷ 92,391 = 0.49

Activity ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted total asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023.

Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Total assets 95,159 96,820 109,314 118,481 129,944
Total BMS shareholders’ equity 29,430 31,061 35,946 37,822 51,598
Solvency Ratio
Financial leverage1 3.23 3.12 3.04 3.13 2.52
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets 92,391 95,476 107,875 117,320 129,434
Adjusted total BMS shareholders’ equity 27,000 31,883 39,008 42,068 57,542
Solvency Ratio
Adjusted financial leverage2 3.42 2.99 2.77 2.79 2.25

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Financial leverage = Total assets ÷ Total BMS shareholders’ equity
= 95,159 ÷ 29,430 = 3.23

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total BMS shareholders’ equity
= 92,391 ÷ 27,000 = 3.42

Solvency ratio Description The company
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.
Bristol-Myers Squibb Co. adjusted financial leverage ratio increased from 2021 to 2022 and from 2022 to 2023.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS 8,025 6,327 6,994 (9,015) 3,439
Total BMS shareholders’ equity 29,430 31,061 35,946 37,822 51,598
Profitability Ratio
ROE1 27.27% 20.37% 19.46% -23.84% 6.66%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net earnings (loss) attributable to BMS 4,737 3,589 5,601 (8,032) 2,515
Adjusted total BMS shareholders’ equity 27,000 31,883 39,008 42,068 57,542
Profitability Ratio
Adjusted ROE2 17.54% 11.26% 14.36% -19.09% 4.37%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 ROE = 100 × Net earnings (loss) attributable to BMS ÷ Total BMS shareholders’ equity
= 100 × 8,025 ÷ 29,430 = 27.27%

2 Adjusted ROE = 100 × Adjusted net earnings (loss) attributable to BMS ÷ Adjusted total BMS shareholders’ equity
= 100 × 4,737 ÷ 27,000 = 17.54%

Profitability ratio Description The company
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity. Bristol-Myers Squibb Co. adjusted ROE deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS 8,025 6,327 6,994 (9,015) 3,439
Total assets 95,159 96,820 109,314 118,481 129,944
Profitability Ratio
ROA1 8.43% 6.53% 6.40% -7.61% 2.65%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net earnings (loss) attributable to BMS 4,737 3,589 5,601 (8,032) 2,515
Adjusted total assets 92,391 95,476 107,875 117,320 129,434
Profitability Ratio
Adjusted ROA2 5.13% 3.76% 5.19% -6.85% 1.94%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 ROA = 100 × Net earnings (loss) attributable to BMS ÷ Total assets
= 100 × 8,025 ÷ 95,159 = 8.43%

2 Adjusted ROA = 100 × Adjusted net earnings (loss) attributable to BMS ÷ Adjusted total assets
= 100 × 4,737 ÷ 92,391 = 5.13%

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted ROA deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.